David A. Williams, MD, Chief of Hematology/Oncology and Director of Translational Research, Boston Children’s Hospital; Associate Chairman of the Department of Pediatric Oncology, Dana-Farber Cancer Institute; Leland Fikes Professor of Pediatrics, Harvard Medical School; and Director of the Pediatric Hematology/Oncology Fellowship Program, Dana-Farber/Children’s Hospital Cancer Center, Boston, MA
Dr. Williams’ major fields of interest include molecular mechanisms that underlie hematopoiesis, gene transfer into hematopoietic stem cells, and the management of children with hematologic diseases. He will serve a one-year term as vice president, followed by successive one-year terms as president-elect and president.
Stephanie J. Lee, MD, MPH, member of the Fred Hutchinson Cancer Research Center, Professor of Medical Oncology, University of Washington School of Medicine, Seattle, WA
Her fields of interest include outcomes and health services research in hematologic malignancies and allogeneic hematopoietic cell transplantation, and late effects of hematopoietic cell transplantation, particularly chronic graft-versus-host disease. She will serve a four-year term as secretary.
Jonathan D. Licht, MD, Johanna Dobe Professor of Medicine, Chief of the Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago; Associate Director, Clinical Sciences at Robert H. Lurie Comprehensive Cancer Center
His major area of interest is epigenetics and aberrant gene expression in hematologic malignancies, including large cell lymphoma, multiple myeloma, and myeloproliferative neoplasms. He will serve a four-year term as councillor.
Margaret A. Shipp, MD, Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School; Chief of the Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute; Director, Lymphoma Program, Dana-Farber/Harvard Comprehensive Cancer Center, Boston, MA
Her major interest areas include clinical and molecular heterogeneity of large B-cell lymphomas and Hodgkin lymphoma, as well as the identification of unique lymphoma subtypes amenable to targeted therapy and mechanisms of immune evasion. She will serve a four-year term as councillor.
back to top